

# TWELVE MONTH ASSESSMENT OF TUMOUR RECURRENCE FOLLOWING A LOCAL, INTRATUMOURAL TIGILANOL TIGLATE (STELFONTA®) INJECTION

## OBJECTIVES

Assess the 12-month incidence of tumour recurrence following a complete response after a local intratumoural tigilanol tiglate injection.

## MATERIALS & METHODS


- **Animals:**
  - 74 dogs were available for assessment.
- **Assessed dogs:**
  - Had received a single tigilanol tiglate dose of 0.5mg tigilanol tiglate per cm<sup>3</sup> tumour volume to a cytologically-confirmed mast cell tumour (MCT) of maximum volume 10 cm<sup>3</sup>; dose rate not exceeding 0.25 mg/kg bodyweight.
  - Achieved a complete response (i.e. complete tumour resolution of target MCT) by 28 days after tigilanol tiglate treatment.
  - Dogs that developed recurrent tumours during this period received a second injection and their subsequent response was then assessed.
- **Clinical Evaluation:**
  - Assessed for recurrence at treatment site over a 12-month period.

## RESULTS

- 65 dogs (88%) had no evidence of local MCT recurrence at the treatment site.
- 9 dogs developed recurrent tumours: 8 achieved a complete response at 28 days following a second injection.

## CLINICAL INTEREST

Administration of a local, intratumoural dose of tigilanol tiglate provided a durable response for the treatment of canine MCT.



## REFERENCES

Campbell JE, Johannes, Chad M, Reddell PW. Durability of Clinical Response to intratumoural tigilanol tiglate in canine MCT. In: 2019 Veterinary Cancer Society Annual Conference [Internet]. 2019.